US-based medical technology company Sunridge International said its patented Pneumatic Trabeculoplasty (PNT) non-invasive treatment for glaucoma and ocular hypertension, is making its mark in China. Introduced into China by Beijing Vision World (BVW) in 2007, the PNT treatment has undergone the most vigorous patient research studies before gaining regulatory approval by China's Federal Drug Administration, earlier this year.

In recent months, Beijing Vision World had presented the PNT treatment at a number of ophthalmologist conferences, expert forums and hospital training seminars in a number of cities throughout China including Beijing, Nanjing, Taiyuan, Wuhan, Changsha and several towns throughout Northeast China. Research papers devoted to PNT have been presented by leading ophthalmic practitioners and academics at several conferences all of which have been reported in news articles and feature stories appearing in China's general and technical publications. Details of the treatment and its impact on glaucoma patients, have been featured on national TV programs.

In summarizing his firm's progress, Mr Yang Waisheng, president of BVW, said he and his marketing team were extremely pleased with the reception given by some of China's most demanding ophthalmologists, eye doctors and hospitals throughout China. "We have made a very good start and it is our intention to continue to demonstrate the PNT approach to the treatment of glaucoma. Our goal is to have PNT taken up by an increasing number of hospitals, clinics and ophthalmic surgeries in China, so that we might reach out to as many glaucoma sufferers as possible throughout this vast country. We are conscious of the fact that many of these patients would otherwise be unable to find treatment to control this pervasive eye disease which is so prevalent in China."

Mr G. Richard Smith, CEO of Sunridge International, said that China represents an enormous marketing opportunity for the PNT equipment and treatment. "We are delighted with the progress and sales made by Mr Yang and his team each month and we are determined to provide maximum sales and marketing support to bear on their efforts to bringing our treatment to the tremendous number of outlets in China."